New data show greater tau reduction at higher doses but strongest clinical signal at lowest dose, raising key questions about optimal dosing in further trials, says the ADDF ... .
Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics ... .
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and ImagingData at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB).